News | May 14, 2026
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
EBITDA before special items decreases to €4.08 billion (7.4%)
Bayer expects 2025 to be the most difficult year of its turnaround
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
EBITDA before special items falls 1.3 percent to € 4.41 billion
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
